Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$56.33 USD

56.33
1,335,270

+0.22 (0.39%)

Updated Aug 29, 2024 04:00 PM ET

After-Market: $56.32 -0.01 (-0.02%) 6:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Kinjel Shah headshot

Is Artificial Intelligence the Next Big Thing in Biotech?

Artificial intelligence can drastically reduce the time taken to develop new life-saving drugs.

    Pharma/Biotech Stocks to Watch This Prostate Cancer Month

    Here we highlight a few companies that are focused on developing treatments for prostate cancer.

      Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars

      Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.

        Regeneron/Sanofi's sBLA for Praluent to be Reviewed by FDA

        The FDA will review Regeneron (REGN) and Sanofi's sBLA for its PCSK9 Inhibitor Praluent to reduce risk of major adverse cardiovascular events.

          Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus

          Novartis (NVS) to sell parts of its Sandoz Unit. AstraZeneca (AZN), Merck (MRK), Pfizer (PFE) and others announce pipeline and regulatory updates.

            Alnylam's Shares Up as Onpattro Gets FDA and EU Approvals

            Shares of Alnylam (ALNY) increase due to the FDA and European approval for Onpattro.

              Sanofi's Blood Disorder Drug Cablivi Gets Approval in Europe

              Sanofi's (SNY) Cablivi receives approval for the treatment of acquired thrombotic thrombocytopenic purpura, a rare blood clotting disorder.

                Alnylam Gets European Nod for First-Ever RNAi Therapeutic

                Alnylam's (ALNY) Onpattro, the first ever RNA interference (RNAi) therapeutic, has been granted marketing authorization by the European Commission.

                  The Zacks Analyst Blog Highlights: Visa, PNC, SAP, Sanofi and Ross

                  The Zacks Analyst Blog Highlights: Visa, PNC, SAP, Sanofi and Ross

                    Emergent (EBS) to Buy Narcan Maker Adapt Pharma for $735M

                    Emergent (EBS) inks a deal to buy Adapt Pharma. This move will add the latter's popular Narcan nasal spray to its portfolio.

                      Mark Vickery headshot

                      Top Research Reports for Visa, PNC Financial & SAP

                      Today's Research Daily features new research reports on 16 major stocks, including Visa (V), PNC Financial Services Group (PNC) and SAP SE (SAP)

                        Zai Lab Stock Down, Atopic Dermatitis Candidate Trial Fails

                        Shares of Zai Lab (ZLAB) decline following the failure of a phase IIA study on its pipeline candidate, ZL-3101, for the treatment of atopic dermatitis.

                          Kinjel Shah headshot

                          Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio

                          The large-cap pharma industry is on track to recovery. Here are two stocks from the space that investors may consider betting on.

                            Regeneron's Eylea Gets FDA Nod for Wet AMD as a 12-Week Dose

                            Regeneron Pharmaceuticals (REGN) gets the FDA approval for the label expansion of its lead drug, Eylea as a treatment for wet AMD with a modified 12-week dosing schedule.

                              Regeneron, Teva Announce Positive Data on Osteoarthritis Drug

                              Regeneron (REGN) along with partner Teva announces positive top-line results from a late-stage candidate on fasinumab in patients with chronic pain from osteoarthritis of the knee or hip.

                                Medtronic Unveils Inner CircleSM Program, Boosts Diabetes Arm

                                Medtronic (MDT) focuses on initiatives to boost its diabetes business.

                                  Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD

                                  Regeneron (REGN) suffers setback as the FDA issues a CRL to its application for label expansion of Eylea for wet AMD with a modified 12-week dosing schedule.

                                    Alnylam (ALNY) Gets FDA Nod for First-Ever RNAi Therapeutic

                                    Alnylam (ALNY) receives FDA approval for Onpattro to treat polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.

                                      Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold

                                      Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.

                                        Roche's (RHHBY) Xolair Gets Breakthrough Therapy Status

                                        Genentech's, a subsidiary of Roche (RHHBY), allergy drug, Xolair, gets Breakthrough Therapy designation in the United States for the prevention of severe food allergic reactions.

                                          Alnylam's (ALNY) Q2 Loss Wider Than Expected, Sales Beat

                                          Alnylam (ALNY) posted wider-than-expected loss in the second quarter of 2018 and received a positive opinion from the CHMP for the marketing authorization of patisiran.

                                            Emergent (EBS) Q2 Earnings and Revenues Surpass Estimates

                                            Emergent Biosolutions (EBS) rides high on earnings as well as revenue beat in Q2.

                                              The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis

                                              The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis

                                                Pharma Stock Roundup: PFE Dominates Headlines, BMY Drug Gets EU Approval

                                                Pfizer (PFE) reports strong second-quarter results. European Commission approves Pfizer and Bristol-Myers' (BMY) medicines.

                                                  BioMarin (BMRN) Q2 Earnings Miss Estimates, Revenues Beat

                                                  BioMarin (BMRN) reports mixed second-quarter results with earnings missing estimates but sales beating the same.